Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

The first annual LaryHacks, a competition to design innovative devices, apps or methods to assist laryngectomy patients who have had their voice boxes removed, has been set for Thursday, April 12, 5 to 8 p.m., in the Wond’ry, 2414 Highland Ave. in the Vanderbilt University Engineering and Science building.

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.

Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer.

Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer.

Ian Macara, PhD, Louise B. McGavock Professor and Chair of Cell and Developmental Biology and co-leader of the Signal Transduction and Chemical Biology Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the Pink Tie Guys for the Susan G. Komen Central Tennessee organization.

Vanderbilt University Medical Center’s (VUMC) Lung Screening Program for patients at high risk for cancer recently reached a milestone, enrolling more than 700 patients and performing more than 1,000 CT screening examinations.